Lipemic anterior chamber mimicking uveitis in severe hypertriglyceridemia: a case report and literature review Authors: Jiaying Lei, Xinxin Lu, Qingfeng Liang Published: 2026 ABSTRACT BackgroundDiffuse milky-white exudation (lipemic aqueous humor) in the anterior chamber is a rare ocular manifestation associated with metabolic disease-related microvascular dysfunction. Early-onset type 2 diabetes mellitus is characterized by severe metabolic disturbances (e.g., dyslipidemia) and early microvascular injury. We report a young female with poorly controlled hyperglycemia/hyperlipidemia presenting with pseudouveitis and marked milky-white anterior chamber exudation (lipemic aqueous humor), initially mimicking a corneal disorder.Case presentationA 33-year-old woman with 5-year type 2 diabetes (poor glycemic control), dyslipidemia, chronic sleep disturbances, and a high-fat/high-sugar diet developed acute left-eye pain, photophobia, and decreased vision during menstruation following travel-related fatigue. Slit-lamp examination showed massive homogeneous milky-white anterior chamber exudation (corneal porcelain-like appearance), and B-scan ultrasonography was unremarkable. Fasting blood tests revealed markedly elevated fasting glucose, triglycerides, and total cholesterol. She was diagnosed with pseudouveitis with anterior chamber lipid-protein exudation, and symptoms improved rapidly within 12 h of intensive topical/periocular corticosteroid therapy; intraocular inflammation largely resolved by day 6, with residual posterior synechiae.ConclusionsEarly-onset type 2 diabetes patients are prone to metabolic dysregulation under physiological/metabolic stress. Persistent hyperglycemia/hyperlipidemia may compromise microvascular integrity and increase permeability, potentially leading to lipid-protein leakage into the anterior chamber (lipemic aqueous humor)—a hypothetical association due to lack of aqueous humor biochemical analysis. This milky exudate is easily misdiagnosed as infectious keratitis, especially with normal B-scan findings. Meticulous slit-lamp examination, adjunctive AS-OCT/UBM, and systemic metabolic evaluation are crucial for accurate diagnosis. Clinicians should promptly assess serum glucose/lipid levels in young patients with milky anterior chamber opacities to avoid misdiagnosis and unnecessary interventions. Background Uveitis is an acute inflammatory disorder that primarily involves the uveal tract and may extend to affect the retina, vitreous, sclera, and optic nerve. In developed countries, uveitis is the third leading cause of irreversible blindness; in developing regions, approximately 25% of blindness cases are attributable to uveitis [1]. Acute uveitis is a relatively common ocular complication in patients with diabetes and is particularly prevalent among those with poor glycemic control and concomitant dyslipidemia. Previous studies have demonstrated a dose–response relationship between glycemic control and the risk of acute uveitis, with worse glycemic regulation associated with higher incidence [2]. However, as a major systemic contributor to ocular disease, disordered lipid metabolism has often received insufficient attention. Elevated lipid levels may increase the risk of uveitis by altering vascular permeability, amplifying inflammatory responses, and promoting lipid deposition within ocular tissues. Because dyslipidemia is frequently asymptomatic and lacks specific early clinical signs, it is often only detected after severe complications have developed. Here, we report a case of a young woman with diabetes and dyslipidemia who developed a large amount of homogeneous milky-white anterior chamber exudation following physical exertion, and we present a review of the relevant literature. Case presentation This case report was prepared in accordance with the CARE guidelines, and the complete CARE checklist is provided as a supplementary file. A 33-year-old female presented to our ophthalmology clinic with a 3-day history of redness, pain, photophobia, and decreased vision in the left eye, accompanied by one day of whitening in the corneal region. She had a 5-year history of type 2 diabetes mellitus, managed with long-term oral hypoglycemic agents, but with poor glycemic control. She reported no prior ocular disease or ocular surgery. The patient also had a 7-year history of moderate-to-severe depression, with intermittent use of antipsychotic medications, chronic sleep disturbances, and a dietary preference for high-fat and high-sugar foods. Notably, her ocular symptoms occurred during her menstrual period, following physical fatigue and sleep disruption associated with travel. Ophthalmologic examination revealed a best-corrected visual acuity (BCVA) of 0.9 in the right eye and 0.1 in the left eye; intraocular pressure (IOP) was 17.1 mmHg in the right eye and 14.0 mmHg in the left eye. Slit-lamp examination of the left eye showed marked eyelid edema and congestion (+++), mixed conjunctival hyperemia and edema (+++), mild corneal edema (+), and the anterior chamber filled with abundant, homogenous, milky-white exudates, obscuring the view of posterior intraocular structures (Figs. 1A–C). Ocular ultrasonography revealed no significant abnormalities (Fig. 2A). During the examination, the patient exhibited marked photophobia and lacrimation, with tenderness over the ciliary body region, and was initially diagnosed with acute anterior uveitis of the left eye. Fig. 1Slit-lamp findings of the left eye during the disease course. Baseline (A–C): Under diffuse illumination, marked conjunctival hyperemia and edema were observed. The cornea appeared porcelain-white due to dense anterior chamber opacity, while the corneal structure itself remained intact (A). Under a narrow slit beam, the aqueous humor showed homogeneous milky turbidity (B–C). Twelve hours after treatment (D–F): Conjunctival hyperemia was decreased, and the corneal grayish-white appearance was reduced, permitting partial visualization of the pharmacologically dilated pupil (D). Narrow-beam illumination revealed resolution of milky anterior chamber turbidity (E–F). Six days after treatment (G–I): Conjunctival hyperemia and edema were markedly improved, and the cornea regained full transparency (G). Anterior chamber opacities were significantly resolved; iris details were clearly visible, and the pupil remained pharmacologically dilated, irregular, with partial posterior synechiae (H–I) Slit-lamp findings of the left eye during the disease course. Baseline (A–C): Under diffuse illumination, marked conjunctival hyperemia and edema were observed. The cornea appeared porcelain-white due to dense anterior chamber opacity, while the corneal structure itself remained intact (A). Under a narrow slit beam, the aqueous humor showed homogeneous milky turbidity (B–C). Twelve hours after treatment (D–F): Conjunctival hyperemia was decreased, and the corneal grayish-white appearance was reduced, permitting partial visualization of the pharmacologically dilated pupil (D). Narrow-beam illumination revealed resolution of milky anterior chamber turbidity (E–F). Six days after treatment (G–I): Conjunctival hyperemia and edema were markedly improved, and the cornea regained full transparency (G). Anterior chamber opacities were significantly resolved; iris details were clearly visible, and the pupil remained pharmacologically dilated, irregular, with partial posterior synechiae (H–I) Fig. 2Ocular imaging findings. B-scan ultrasonography of the left eye showed no detectable abnormalities in the anterior chamber (A). Optical coherence tomography (OCT) revealed marked retinal and choroidal edema involving the macular and perimacular regions in the left eye (C) compared with the right eye (B) Ocular imaging findings. B-scan ultrasonography of the left eye showed no detectable abnormalities in the anterior chamber (A). Optical coherence tomography (OCT) revealed marked retinal and choroidal edema involving the macular and perimacular regions in the left eye (C) compared with the right eye (B) Given the patient’s acute severe symptoms (visual acuity 0.1, massive anterior chamber exudation, and intense ocular pain/photophobia) and nighttime outpatient presentation (limiting additional diagnostic testing), a sub-Tenon’s injection of tobramycin sulfate (20 mg), dexamethasone sodium phosphate (3 mg), and lidocaine hydrochloride (10 mg) was administered, combined with topical tobramycin/dexamethasone combination eye drops every 2 h and atropine sulfate ophthalmic gel every 4 h in the left eye. This regimen was selected based on initial differential diagnosis that excluded major infectious etiologies (no contact lens wear/ocular trauma, intact corneal epithelium, normal white blood cell count, and negative systemic infection screenings) and the working diagnosis of acute anterior uveitis, with periocular administration chosen to rapidly deliver medication to the severely affected iris-ciliary body while avoiding oral steroid side effects. The initial therapy was administered cautiously, with only one type of glucocorticoid used for the sub-Tenon’s injection. Twelve hours after treatment, the patient reported significant symptom relief. Slit-lamp examination revealed marked reduction of eyelid and conjunctival edema, decreased corneal haze, partial absorption of anterior chamber exudates, and visualization of iris texture and a mydriatic pupil (Figs. 1D–F). Posterior segment optical coherence tomography (OCT) and fundus photography revealed significant retinal and choroidal edema in the left eye (Figs. 2B–C and 3A–B). Systemic laboratory testing showed a white blood cell count of 8.34 × 10⁹/L (reference 3.5–9.5 × 10⁹/L), markedly elevated fasting blood glucose at 20.9 mmol/L (reference 3.9–6.1 mmol/L), and glycated hemoglobin (HbA1c) of 14.7% (reference 4.3–5.8%). Serum biochemistry revealed decreased creatinine (30.3 µmol/L, reference 41–73 µmol/L), significantly elevated uric acid (561 µmol/L, reference 90–360 µmol/L), elevated γ-glutamyl transferase (125 U/L, reference 7–45 U/L), normal aspartate aminotransferase (11 U/L, reference 13–35 U/L), and mildly elevated alkaline phosphatase (111 U/L, reference 35–100 U/L). Lipid profile testing confirmed severe dyslipidemia, with triglycerides of 31.52 mmol/L (reference 0.56–1.70 mmol/L), total cholesterol of 11.00 mmol/L (reference 2.10–5.17 mmol/L), and reduced high-density lipoprotein cholesterol at 0.41 mmol/L (reference 1.04–1.60 mmol/L). Urinalysis indicated strongly positive glucosuria (++++). Autoantibody panels, human leukocyte antigen B27 (HLA-B27) testing, sacroiliac joint computed tomography (CT), chest radiography, tuberculosis T-cell spot test (T-SPOT.TB), and interferon-γ release assay were all unremarkable, effectively excluding tuberculosis and other systemic infections. Fig. 3Fundus imaging during the disease course. Baseline: Compared with the healthy right eye (A), the left-eye fundus image was blurred, and the macular region showed subtle retinal whitening, consistent with media opacity and associated retinal edema (B). Six days after treatment: Image clarity was improved (D). The macular and adjacent retina remained slightly paler than in the right eye (C), indicating partial restoration of media transparency but persistent mild retinal edema. Nevertheless, retinal edema was markedly reduced compared with baseline (B) Fundus imaging during the disease course. Baseline: Compared with the healthy right eye (A), the left-eye fundus image was blurred, and the macular region showed subtle retinal whitening, consistent with media opacity and associated retinal edema (B). Six days after treatment: Image clarity was improved (D). The macular and adjacent retina remained slightly paler than in the right eye (C), indicating partial restoration of media transparency but persistent mild retinal edema. Nevertheless, retinal edema was markedly reduced compared with baseline (B) Acute uveitis can be classified according to etiology into inflammatory uveitis and pseudouveitis. Clinically, typical inflammatory uveitis is caused by immune reactions and usually involves infiltration of inflammatory cells, manifesting as the accumulation of anterior chamber cells and inflammatory exudates. Common causes include autoimmune diseases, infectious diseases, and others. In contrast, metabolic disorders (such as diabetes mellitus and hyperlipidemia) can lead to lipid and protein leakage into the anterior chamber, which, although presenting with clinical features similar to inflammatory uveitis, fundamentally does not involve an immune-mediated inflammatory response. The turbidity in the anterior chamber is typically due to the accumulation of lipids and proteins, without infiltration of inflammatory cells. Therefore, this condition is referred to as pseudouveitis. The clinical manifestations of the patient in this study are consistent with pseudouveitis. Notably, the homogeneous milky-white exudation in the anterior chamber is a typical feature of lipemic aqueous humor, which is closely associated with severe hypertriglyceridemia. Accordingly, the final diagnosis was Pseudouveitis of the left eye, left retinal edema, Type 2 Diabetes Mellitus (poor glycemic control), and Hyperlipidemia. Based on the findings, the treatment regimen was adjusted as follows: subconjunctival injection of dexamethasone sodium phosphate (3 mg), atropine sulfate (0.25 mg), lidocaine hydrochloride (20 mg), and epinephrine hydrochloride (0.2 mg) once daily for three days; sub-Tenon’s injection of compound betamethasone (6 mL) combined with lidocaine hydrochloride (20 mg) every other day for three sessions. The tobramycin/dexamethasone combination eye drops were continued 10 times per day initially, with the frequency reduced by one instillation every two days. Given the predominant involvement of the iris–ciliary body, this periocular regimen was selected to enhance anterior uveal drug delivery: the subconjunctival injection provided rapid, high-concentration steroid exposure to the inflamed tissues, while the posterior sub-Tenon depot ensured sustained diffusion toward the ciliary body and peripheral choroid. Additionally, compound tropicamide eye drops were applied once daily, and atropine sulfate ophthalmic gel once nightly to the left eye. Meanwhile, the patient was strongly advised to initiate standardized oral hypoglycemic therapy and modify her dietary pattern (reducing high-fat/high-sugar intake); however, standardized intensive lipid-lowering or insulin therapy was not initiated during the acute ocular treatment phase due to the patient’s poor treatment compliance. The patient received outpatient management throughout the course, with no hospitalization, and the degree of her adherence to the advised hypoglycemic therapy remained unclear, resulting in failure to achieve strict glycemic and lipid control during the acute treatment period. Intraocular pressure was monitored daily throughout treatment, and no elevation or steroid-related IOP response was observed. After six days of treatment, BCVA improved to 0.4 in the left eye, and intraocular pressure was 17.3 mmHg. The eyelid and conjunctival edema were markedly reduced, the cornea had regained transparency, and the anterior chamber exudate had largely resolved. The iris pattern was clearly visible, and the pupil remained pharmacologically dilated, slightly irregular, with partial posterior synechiae (Fig. 1G–I). Retinal edema in the left eye showed significant improvement (Fig. 3C–D). Given that the patient’s visual acuity had not fully recovered—likely due to residual retinal and choroidal edema as well as mild vitreous inflammatory haze—an additional treatment was administered. The left eye received a subconjunctival injection of dexamethasone sodium phosphate (3 mg), atropine sulfate (0.25 mg), lidocaine hydrochloride (20 mg), and epinephrine hydrochloride (0.2 mg). On day seven, a sub-Tenon’s injection of compound betamethasone (6 mL) combined with lidocaine hydrochloride (20 mg) was performed. Concurrently, the patient continued topical therapy in the left eye with prednisolone acetate eye drops, compound tropicamide eye drops, and atropine sulfate ophthalmic gel. Considering that the patient’s condition had stabilized and that prolonged stay in the travel destination was inconvenient, it was agreed that she could return to her hometown for continued follow-up and outpatient management. She was referred to the endocrinology department for optimization of systemic blood glucose and lipid control. Follow-up One month after symptom resolution, the patient was contacted for follow-up. Because she had returned to her hometown shortly after clinical improvement, subsequent examinations and treatment were completed at a local medical facility. According to the follow-up report, her left-eye visual acuity had recovered to the pre-morbid level of 1.0, with no recurrence of ocular discomfort or inflammatory symptoms. Systemic metabolic control had also improved substantially, with both blood glucose and lipid levels maintained within the target ranges. Given the well-established positive correlation between diabetes duration and microvascular complications, the patient was advised to undergo long-term monitoring of glycemic and lipid profiles and to maintain strict metabolic control to reduce the risk of recurrent microvascular injury or future episodes of pseudouveitis. Discussion Homogeneous milky-white exudation in the anterior chamber is an extremely rare ocular manifestation, with only seven cases reported to date [3, 9] (summarized in Table 1). Most reported cases involve middle-aged male patients with poorly controlled diabetes, presenting with a 2–5 day disease course, moderate to severe visual loss, homogeneous milky-white anterior chamber exudation without keratic precipitates, and no inflammatory or purulent exudate in the aqueous humor, all accompanied by markedly elevated blood glucose and lipid levels. Except for patients who underwent anterior chamber lavage [9], the remaining cases achieved rapid resolution of anterior chamber lesions after treatment with topical glucocorticoids combined with systemic glucose and lipid-lowering therapy, which supports the rationality of our decision to forgo anterior chamber paracentesis and lavage after a comprehensive risk-benefit assessment in the present case. Based on the clinical characteristics of this case and the patterns of published literature, this discussion will elaborate on the high-risk population, core associated factors, nature and identification of anterior chamber exudation, causes of misdiagnosis by B-scan ultrasonography, and potential transient triggers of the condition, aiming to provide clinical insights for the diagnosis and management of this rare ocular manifestation. Table 1Available reports on chylous aqueous humorNo.AgeGenderEyeBlood glucose level(3.9–6.1 mmol/L)Triglyceride Level(0.56–1.70 mmol/L)DiagnosisEffective Treatment RegimenFollow-up1344MaleOS for 5d24 mmol/L38 mmol/LAnterior pseudouveitis in OS, DM, HTN, HLP, Obesity, DRSystemic: Insulin for lowering blood glucose, fibrates for regulating blood lipidsCRVO in left eye, 6 weeks later2432MaleOD for 3d13.9 mmol/L65.5 mmol/LLipemic aqueous humor in OD, Lipemia retinalis in OS, T2DM, DKA, HLP, SchizophreniaSystemic: Insulin + fluid replacement for DKA, fat-free dietOcular: Topical glucocorticoid eye dropsNone3543MaleOD for 2d27mmol/L25mmol/LAnterior pseudouveitis in OD, DM, HLP, HTNSystemic: Hypoglycemic and lipid-lowering therapyOcular: Predforte eye drops, homatropine eye dropsIOP of right eye increased 2 weeks later4631MaleOD for 3d14.50mmol/L13.55mmol/LAcute uveitis、Secondary glaucoma in OD, T2DM, DKA, HLPSystemic: Hypoglycemic/lipid-lowering agents and fluid replacement for DKAOcular (OD): Ocular (OD)༚Hormone 、 mydriatic 、intraocular pressure-lowering eye drops, plus 3 mg dexamethasone periocular injectionNone5739MaleOD for 3d12.8 mmol/L18.1mmol/LChylous aqueous humor、CRVO、DME in OD, Lipemia retinalis in OS, DM, HLPSystemic: Insulin for lowering blood glucose; acipimox for reducing blood lipidsTopical: GC, PRP, IVI anti-VEGF therapyNVI in right eye, 1 day later6860MaleOS for 5d26mmol/L/Diabetic keratopathy, Anterior uveitis in OS, DR in OU, T2DMSystemic: Hypoglycemic therapyOcular: Mydriatic and glucocorticoid agentsNone7937FemaleOU for 3d16.5mmol/L16.4mmol/LChylous aqueous humor、DR、Lipemia retinalis in OU, Secondary glaucoma in OD, T2DM, HLP, History of mental disorderSystemic: Hypoglycemic/lipid-lowering agents, strict fat intake controlOcular: Glucocorticoids, cycloplegics, IOP-lowering drugs; right anterior chamber irrigationIOP of both eyes increased 1 day laterOurs33FemaleOS for 3d20.9mmol/L31.5mmol/LAcute anterior uveitis、Retinal and choroidal edema in OS, T2DM, HLP, DepressionSystemic: Hypoglycemic/lipid-lowering agents, dietary adjustmentOcular: Eye drops and Periocular injection of glucocorticoids and cycloplegicsNone Table 1Available reports on chylous aqueous humorNo.AgeGenderEyeBlood glucose level(3.9–6.1 mmol/L)Triglyceride Level(0.56–1.70 mmol/L)DiagnosisEffective Treatment RegimenFollow-up1344MaleOS for 5d24 mmol/L38 mmol/LAnterior pseudouveitis in OS, DM, HTN, HLP, Obesity, DRSystemic: Insulin for lowering blood glucose, fibrates for regulating blood lipidsCRVO in left eye, 6 weeks later2432MaleOD for 3d13.9 mmol/L65.5 mmol/LLipemic aqueous humor in OD, Lipemia retinalis in OS, T2DM, DKA, HLP, SchizophreniaSystemic: Insulin + fluid replacement for DKA, fat-free dietOcular: Topical glucocorticoid eye dropsNone3543MaleOD for 2d27mmol/L25mmol/LAnterior pseudouveitis in OD, DM, HLP, HTNSystemic: Hypoglycemic and lipid-lowering therapyOcular: Predforte eye drops, homatropine eye dropsIOP of right eye increased 2 weeks later4631MaleOD for 3d14.50mmol/L13.55mmol/LAcute uveitis、Secondary glaucoma in OD, T2DM, DKA, HLPSystemic: Hypoglycemic/lipid-lowering agents and fluid replacement for DKAOcular (OD): Ocular (OD)༚Hormone 、 mydriatic 、intraocular pressure-lowering eye drops, plus 3 mg dexamethasone periocular injectionNone5739MaleOD for 3d12.8 mmol/L18.1mmol/LChylous aqueous humor、CRVO、DME in OD, Lipemia retinalis in OS, DM, HLPSystemic: Insulin for lowering blood glucose; acipimox for reducing blood lipidsTopical: GC, PRP, IVI anti-VEGF therapyNVI in right eye, 1 day later6860MaleOS for 5d26mmol/L/Diabetic keratopathy, Anterior uveitis in OS, DR in OU, T2DMSystemic: Hypoglycemic therapyOcular: Mydriatic and glucocorticoid agentsNone7937FemaleOU for 3d16.5mmol/L16.4mmol/LChylous aqueous humor、DR、Lipemia retinalis in OU, Secondary glaucoma in OD, T2DM, HLP, History of mental disorderSystemic: Hypoglycemic/lipid-lowering agents, strict fat intake controlOcular: Glucocorticoids, cycloplegics, IOP-lowering drugs; right anterior chamber irrigationIOP of both eyes increased 1 day laterOurs33FemaleOS for 3d20.9mmol/L31.5mmol/LAcute anterior uveitis、Retinal and choroidal edema in OS, T2DM, HLP, DepressionSystemic: Hypoglycemic/lipid-lowering agents, dietary adjustmentOcular: Eye drops and Periocular injection of glucocorticoids and cycloplegicsNone Available reports on chylous aqueous humor Systemic: Insulin + fluid replacement for DKA, fat-free diet Ocular: Topical glucocorticoid eye drops Systemic: Hypoglycemic and lipid-lowering therapy Ocular: Predforte eye drops, homatropine eye drops Systemic: Hypoglycemic/lipid-lowering agents and fluid replacement for DKA Ocular (OD): Ocular (OD)༚Hormone 、 mydriatic 、intraocular pressure-lowering eye drops, plus 3 mg dexamethasone periocular injection Systemic: Insulin for lowering blood glucose; acipimox for reducing blood lipids Topical: GC, PRP, IVI anti-VEGF therapy Systemic: Hypoglycemic therapy Ocular: Mydriatic and glucocorticoid agents Systemic: Hypoglycemic/lipid-lowering agents, strict fat intake control Ocular: Glucocorticoids, cycloplegics, IOP-lowering drugs; right anterior chamber irrigation Systemic: Hypoglycemic/lipid-lowering agents, dietary adjustment Ocular: Eye drops and Periocular injection of glucocorticoids and cycloplegics Young patients with diabetes: a potential high-risk group for this ocular condition Analysis of the cases in Table 1 shows that all but one patient were aged 30–45 years, suggesting that younger patients with diabetes may face a higher risk of developing this ocular condition. Emerging evidence indicates that patients with early-onset type 2 diabetes often exhibit more pronounced insulin resistance, central obesity, and dyslipidemia (characterized by elevated small dense low-density lipoprotein and reduced high-density lipoprotein) [10, 11]. In addition, irregular lifestyle habits such as a high-fat and high-sugar diet and sleep disturbances are prevalent in this population [10, 12], which further lead to suboptimal metabolic control and increase the vulnerability of ocular microvessels. A cohort study [12] reported that patients with early-onset (< 30 years) type 2 diabetes had a significantly higher prevalence of diabetic nephropathy (40.2%) and a shorter time to onset (4.3 years) compared with age-matched patients with type 1 diabetes (10.1%, 11.0 years, P < 0.001), highlighting the accelerated progression of microvascular injury in early-onset type 2 diabetes. This pathological feature may be a potential contributing factor to the occurrence of this rare anterior chamber lesion in young diabetic patients in the limited reported cases. However, this inference is solely based on the extremely small number of 7 published cases to date and cannot be generalized to the entire population of young diabetic patients, requiring further validation by large-sample clinical studies. Severe hypertriglyceridemia: the core associated factor of anterior chamber exudation Data summarized in Table 1 show that all patients with milky-white anterior chamber exudation (lipemic aqueous humor) have severe glucose and lipid metabolic disorders, and are often complicated with microvascular complications such as diabetic retinopathy, neovascular glaucoma, central retinal vein occlusion, and lipemia retinalis [3–9], suggesting a close potential association between lipemic aqueous humor (a core feature of pseudouveitis) and severe hypertriglyceridemia. Hyperlipidemia is a well-documented cause of abnormal lipid deposition and exudation in ocular tissues: clinical studies have confirmed that plasma triglyceride levels exceeding 11.3 mmol/L can result in lipemic blood [13], and levels over 22.6 mmol/L are associated with the development of lipemia retinalis [14, 15]. Among the different types of hyperlipidemia, Type V hyperlipidemia, which is characterized by chylomicron metabolism disorders, is the most commonly associated with such ocular lipid exudation manifestations [16]. This type of hyperlipidemia is often secondary to poor dietary habits and inadequate diabetes control, both of which were present in our patient, indicating that her severe hypertriglyceridemia may be a secondary consequence of long-term poorly controlled blood glucose. Additionally, some patients in the reported cases [3–9] and the present patient have a history of psychiatric disorders and antipsychotic medication use. Such drugs can induce increased appetite, weight gain, insulin resistance, and dyslipidemia through multiple receptor-mediated mechanisms [17, 18], which further exacerbate metabolic disturbances. This finding emphasizes the necessity of regular monitoring of metabolic indicators such as blood glucose and lipids in patients receiving long-term antipsychotic therapy. Notably, long-standing poorly controlled hyperglycemia combined with hyperlipidemia is hypothesized to be closely associated with impaired vascular endothelial function [19], a pathological association that has been fully verified in diabetic nephropathy and diabetic retinopathy. This common microvascular injury mechanism may also be involved in the disruption of the blood-aqueous barrier in the present case, laying a pathological foundation for the leakage of macromolecular substances into the anterior chamber. This inference is supported by a previously reported case [3], in which anterior chamber paracentesis and aqueous humor biochemical testing confirmed the exudate was primarily composed of lipids and proteins. Nature and clinical identification of anterior chamber exudation Possible components and disease nature of anterior chamber exudation Under physiological conditions, the intact blood-aqueous barrier effectively prevents large molecular substances in the blood, such as lipoproteins, cholesterol, and triglycerides, from leaking into the anterior chamber. Chylomicrons, the main carriers of exogenous triglycerides, have a diameter of 75–1000 nm and a density close to that of aqueous humor [7], and their abnormal accumulation in the blood is the core pathological basis of lipemic blood and ocular lipid exudation. The present patient had a fasting triglyceride level approximately 18 times higher than the normal range, indicating a severe chylomicron metabolism disorder, which is the key pathological factor leading to the occurrence of anterior chamber exudation. In combination with the clinical and laboratory findings of this case, the anterior chamber exudation—defined as lipemic aqueous humor—is considered to be a metabolic ocular lesion caused by lipid-protein leakage from the systemic circulation, rather than an inflammatory lesion induced by pathogens or immune reactions. This judgment is consistent with the clinical characteristics of pseudouveitis reported in the literature [3], where anterior chamber paracentesis and aqueous humor testing confirmed the exudate was rich in lipids and proteins. Clinical basis for diagnosing lipid-protein leakage as the cause of anterior chamber exudation The diagnosis that the anterior chamber exudation in this case was mainly caused by lipid-protein leakage from the blood circulation was based on comprehensive clinical manifestations, auxiliary examinations, and systematic differential diagnosis. First, the patient presented with homogeneous milky-white exudation in the anterior chamber without gravity-dependent layering, which was inconsistent with the clinical characteristics of hypopyon (mainly composed of neutrophils and necrotic tissue with typical liquid level formation). Second, the patient had no history of contact lens wear or ocular trauma, with intact corneal epithelium and stroma, no ulceration or inflammatory infiltration, normal peripheral white blood cell count, and negative results of systemic infection screening, effectively excluding infectious keratitis as the cause of anterior chamber exudation. Third, there were no inflammatory cells or keratic precipitates in the anterior chamber, and the exudation showed no strand or clump-like changes, which was not consistent with fibrinous exudation induced by inflammatory reactions. In addition, the patient’s symptoms improved rapidly after receiving glucocorticoid therapy combined with systemic metabolic control, which further supported the metabolic nature of the anterior chamber exudation. The absence of aqueous humor analysis is a deficiency of this case, and the above judgment is based on clinical inference without direct biochemical verification. Therefore, the proposed lipid-protein leakage mechanism remains hypothetical in the context of the present study, despite support from a previously reported case [3]. It is important to acknowledge that the use of corticosteroids without prior microbiological confirmation carries a potential risk of masking underlying infectious etiologies, though this risk was deemed acceptable given the systematic exclusion of infectious factors and the urgency of relieving the patient’s severe acute symptoms. Causes of missed diagnosis of anterior chamber exudation by B-scan ultrasonography A key clinical finding in this case is that the obvious lipemic aqueous humor (milky-white anterior chamber exudation) was not detected by conventional B-scan ultrasonography, and the underlying causes of this missed diagnosis are closely related to the physical properties of lipemic aqueous humor and the technical characteristics of B-scan ultrasonography. The anterior chamber exudation in this case was composed of submicron-sized lipid-protein particles and emulsified droplets, which were uniformly dispersed in the aqueous humor [20, 21]. On the one hand, the particle size of these components is close to or even lower than the spatial resolution threshold of conventional ocular B-scan ultrasonography (approximately 50–100 μm), making it impossible for the instrument to identify such fine particulate matter. On the other hand, the acoustic impedance of lipid-protein components is almost identical to that of aqueous humor [20], resulting in no obvious acoustic contrast between the exudation and the surrounding aqueous humor, so B-scan ultrasonography cannot form a detectable abnormal signal. For such anterior chamber exudation with special components, advanced imaging examinations such as anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) have higher diagnostic value, which can clearly show the morphological characteristics and distribution of the exudation through higher resolution and better tissue contrast [22, 23]. Potential transient triggers of anterior chamber exudation onset The acute onset of anterior chamber exudation in this patient occurred during menstruation, following physical fatigue and sleep disturbance caused by travel, suggesting that the superposition of transient physiological stress factors on the basis of chronic metabolic disorders may be the inducement of the acute onset of the condition. Chronic sleep disturbance can induce a state of low-grade systemic inflammation and oxidative stress, and cause autonomic nervous system dysregulation, which further increases vascular endothelial permeability [24, 25]. The sharp decline in estrogen levels during menstruation reduces the production of endothelial nitric oxide and weakens the protective effect of estrogen on vascular endothelium [2], which further exacerbates the instability of the already damaged microvessels in diabetic patients. Acute physical fatigue can enhance sympathetic nerve activation and increase the release of catecholamines, which further promotes oxidative injury of vascular endothelial cells [26]. The combined effect of the above factors may transiently increase the permeability of the blood-aqueous barrier and trigger the leakage of lipid-protein substances into the anterior chamber. However, all the above inferences lack specific clinical data support of the patient, and the mechanism has not been verified in this case, so it cannot be regarded as a definitive causal factor for the onset of the condition; this conclusion is only a clinical speculation and requires more clinical cases for further verification. Interpretation of therapeutic effects and importance of long-term metabolic control The rapid symptom improvement (within 12 h) following periocular corticosteroid therapy primarily reflects the acute anti-inflammatory and vascular permeability-reducing effects of the steroids, which alleviated the massive anterior chamber exudation and associated symptoms. Given that the patient received outpatient management without hospitalization, did not achieve strict glycemic or lipid control during the acute treatment phase, and the degree of adherence to the advised hypoglycemic therapy remained unclear, spontaneous lipoprotein clearance or significant metabolic stabilization is unlikely to be the primary driver of immediate symptom relief. However, we acknowledge that any attempted adherence to the advised hypoglycemic therapy may have contributed to potential gradual metabolic improvement, which supported sustained recovery. It is critical to emphasize that while periocular corticosteroids effectively address acute ocular manifestations, long-term strict control of blood glucose and lipids—through standardized pharmacotherapy and lifestyle modification—is the fundamental measure to prevent recurrence of lipemic aqueous humor and pseudouveitis. This aligns with previous reports [3–9], where successful long-term outcomes relied on adequate metabolic management in addition to acute ocular interventions. Limitations This study has several limitations that need to be acknowledged. First, dense anterior chamber exudation partially limited the visualization of the posterior segment during the acute phase, and the absence of optical coherence tomography angiography (OCT-A) examination made it impossible to evaluate the microvascular perfusion status of the retina and choroid, which restricted the in-depth analysis of the posterior segment microvascular changes in the patient. Second, the diagnosis of anterior chamber exudation was only based on slit-lamp examination and B-scan ultrasonography, without the supplementation of advanced anterior segment imaging examinations such as AS-OCT and UBM. The latter can provide more detailed morphological information of the anterior chamber and exudation, and the absence of these examinations reduced the comprehensiveness of the diagnosis. Third, the most critical limitation of this study is the complete absence of aqueous humor analysis: no anterior chamber paracentesis, cytological examination, lipid quantitative detection, or microbiological testing was performed, so the conclusion that the anterior chamber exudation is caused by lipid-protein leakage is only a clinical inference based on the patient’s metabolic status and clinical manifestations, and the specific components of the exudation cannot be definitively confirmed. Fourth, the discussion on the transient physiological stress factors as the inducement of the acute onset of the condition is purely speculative, lacking specific experimental data and clinical indicators to support the relevant mechanism, and cannot form a definitive causal conclusion. Fifth, due to the constraints of outpatient management during the acute phase, a systematic evaluation of diabetic retinopathy and other systemic microvascular complications was not performed for the patient, which made it impossible to comprehensively analyze the correlation between the patient’s systemic microvascular injury and ocular anterior chamber lesions. Conclusion This case supports an associative link between poorly controlled blood glucose/lipids, microvascular endothelial injury, and anterior chamber lipid leakage (lipemic aqueous humor) in young patients, which may mimic corneal opacity—this observation generates a testable hypothesis rather than confirming causality. The homogeneous milky exudate is easily misdiagnosed as infectious keratitis, particularly when B-scan ultrasonography is unremarkable (due to similar acoustic impedance between lipid-protein components and aqueous humor). Clinicians should remain vigilant for such opacities: careful slit-lamp biomicroscopy combined with AS-OCT/UBM is essential to characterize exudate morphology; aqueous humor sampling may be warranted if uncertainty persists. Early differentiation from infectious corneal disease avoids unnecessary antimicrobial therapy or invasive procedures, reducing complications like posterior synechiae and secondary ocular hypertension. Notably, hyperlipidemia’s ocular impacts are often overlooked. In poorly controlled diabetic patients, concurrent hyperlipidemia increases risks of ocular complications (lipemia retinalis, neovascular glaucoma) and systemic adverse events (coronary heart disease, stroke). Timely diagnosis of lipemic aqueous humor/Pseudouveitis and acute ocular interventions (e.g., periocular corticosteroids) rapidly relieve symptoms, but long-term strict metabolic control via standardized pharmacotherapy and lifestyle modification is the fundamental measure to prevent recurrence and systemic complications.